Sugi Predict

Sugi Predict / Targets / CACNG3

CACNG3

Voltage-dependent calcium channel gamma-3 sub · O60359 · CACNG3 on Sugi Atlas →

6,674 patent compounds predicted against CACNG3, 2,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20
SCHEMBL3248439 SCHEMBL3248439 0.45 5/20

Clinical trials — most relevant to CACNG3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Pharmacogenetics and Cardiovascular Events nanCOMPLETED
The Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Working Memory nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies nanUNKNOWN
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Exploring the Genetics of Neuropathic Pain nanRECRUITING
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation. nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Pregabalin Phonophoresis and MET for Knee Osteoarthritis nanRECRUITING
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNG3 binder may also engage these)

ProteinNameSimilarity
Q8VHX0 — 1.000 Q8VHX0 →
Q5R5X2 — 1.000 Q5R5X2 →
Q4R589 — 1.000 Q4R589 →
Q0VD05 — 1.000 Q0VD05 →
Q9JJV5 — 1.000 Q9JJV5 →
CACNG2 Voltage-dependent calcium channel gamma-2 sub 0.998 landscape →
Q71RJ2 — 0.998 Q71RJ2 →
O88602 — 0.998 O88602 →
Q8VHW9 — 0.972 Q8VHW9 →
CACNG4 Voltage-dependent calcium channel gamma-4 sub 0.970 landscape →
Q4V922 — 0.970 Q4V922 →
Q8R1W2 — 0.967 Q8R1W2 →
Q3SZX0 — 0.967 Q3SZX0 →
Q6AYL2 — 0.966 Q6AYL2 →
Q9NV29 — 0.966 Q9NV29 →
Q923Z0 — 0.966 Q923Z0 →
Q7ZWN9 — 0.966 Q7ZWN9 →
Q569C0 — 0.966 Q569C0 →
Q9H2E6 — 0.965 Q9H2E6 →
O42582 — 0.965 O42582 →
W5P3P0 — 0.965 W5P3P0 →
P56749 — 0.965 P56749 →
Q5R9K1 — 0.965 Q5R9K1 →
O42581 — 0.965 O42581 →
Q5VW38 — 0.964 Q5VW38 →
P22831 — 0.964 P22831 →
Q9JJV4 — 0.963 Q9JJV4 →
Q32LT7 — 0.963 Q32LT7 →
O70610 — 0.963 O70610 →
Q148L1 — 0.963 Q148L1 →